Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis - this project will investigate the mechanism by which…

Active Grant Awarded

Award ID
R15CA309616
Recipient
Awarding agency
Obligated
$564,078

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 6% complete
Place of performance
Camden, NJ 08103, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Cancer Institute, within the Department of Health and Human Services, awarded Rowan University Grant R15CA309616 on September 23, 2026, obligating $564,078 under the Cancer Biology Research program (CFDA 93.396). The program supports fundamental cancer research, including tumor biology and metastasis. This award funds a project investigating how mechanical signaling through the inner nuclear envelope protein emerin modulates breast cancer metastasis, with a focus on triple-negative breast cancer. The project hypothesizes that reduced emerin expression or function drives metastatic transformation by compromising nuclear structural integrity, which allows cancer cells to migrate through dense extracellular matrix. The source states that the recipient's prior work showed restored emerin stiffened the nucleus and limited invasion and metastasis in preclinical models. Work is performed in Camden, New Jersey 08103. The period of performance runs from the September 23, 2026 award date to the ultimate completion date of August 31, 2029.

Description

Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis - this project will investigate the mechanism by which mechanical signaling through the inner nuclear envelope protein emerin modulates breast cancer metastasis. Triple-negative breast cancer (TNBC) remains one of the most lethal and therapeutically challenging subtypes of breast cancer due to its high propensity for metastasis and high rates of treatment resistance. To counter this resistance, IT is incumbent on US to examine other, potentially overlooked mechanisms contributing to TNBC's ability to invade tissues and metastasize. Our laboratory has identified a previously unrecognized mechanism by which TNBC cells acquire metastatic potential through alterations in nuclear mechanics. For a tumor to metastasize, cancer cells must traverse the nearby vessels, squeezing through small gaps in the endothelium. The major physical barrier to cells moving through these narrow gaps is the size and stiffness of the nucleus. These nuclear properties are governed by emerin, whose protein levels correlate with overall survival in patients, suggesting that emerin plays a central role in progression of malignant tissues. We showed that decreased expression of emerin, a key regulator of nuclear stiffness, is associated with more aggressive TNBC phenotypes. Reduced emerin levels facilitate nuclear deformability, enabling cancer cells to migrate through dense extracellular matrix (ECM) and disseminate. Restoring emerin stiffens the nucleus, thereby limiting invasion and metastasis in preclinical models. We hypothesize that reduced emerin expression or function acts as a key driver of breast cancer metastatic transformation by compromising the structural integrity of the nucleus. Previous work revealed that cancer nuclear stiffness is impacted by the tumor microenvironment (TME), as increased ECM stiffness causes decreased nuclear stiffness, both of which correlate with increased metastasis. Importantly, we demonstrated that increased ECM stiffness downregulates emerin protein levels, suggesting that emerin plays a key role in responding to changes in the ECM by altering nuclear structure. How IT does this is unclear. The linker of nucleoskeleton and cytoskeleton (LINC) complex is the major conduit for transducing mechanical signals (i.e., changes in ECM stiffness) from the cell surface to the nucleus. Prior research revealed that changes in substrate stiffness caused LINC-dependent changes in the nucleoskeleton and in the expression of pro-migratory proteins, both of which are known to be affected by emerin. However, IT remains to be determined 1) how ECM stiffness is transduced by the LINC complex to the nucleus and how IT affects emerin levels, 2) how emerin's interactions with the LINC complex affect specific emerin functions, and 3) if LINC-mediated pro-metastatic signaling is dependent on emerin. This work will identify targetable regulators of emerin and define how the TME promotes tumor progression via LINC mechanotransduction. Both of these discoveries are clinically valuable, as they may lead to new therapeutic targets and a new set of at-risk criteria that may transform TNBC treatment.

Quick answers

Who received award R15CA309616?

R15CA309616 was awarded to Rowan University by National Cancer Institute (National Institutes of Health) on September 23, 2026.

How much is award R15CA309616 worth?

$564,078 has been obligated on R15CA309616.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award